| Covariate |
Category |
Frequency n (%) |
Deaths n (%)a |
2-YearSurvival (%) |
Log-rank test (p-value) |
| Overall |
|
2079 (100) |
367(22.67)/1619 (17.65) |
71 (66, 74) |
|
| Sex |
Male |
1290 (62.14) |
215/998 (21.54) |
69 (63, 75) |
0.19 |
| |
Female |
786 (37.86) |
151/619 (24.39) |
72 (67, 77) |
| Age |
18-24 |
286 (13.89) |
45/232 (19.40) |
71 (56, 82) |
<0.05 |
| |
25-34 |
655 (31.81) |
120/495 (24.24) |
68 (60, 74) |
| |
35-44 |
645 (31.33) |
133/492 (27.03) |
66 (58, 72) |
| |
> 45 |
473 (22.97) |
67/384 (17.45) |
79 (71, 86) |
| Year of diagnosis |
1996 - 2000 |
139 (6.69) |
20/104 (19.23) |
77 (61, 87) |
0.04 |
| |
2001 |
359 (17.27) |
47/267 (17.60) |
78 (69, 84) |
| |
2002 |
557 (26.79) |
102/453 (22.52) |
67 (56, 75) |
| |
2003 |
546 (26.26) |
127/440 (28.86) |
68 (62, 73) |
| |
2004 |
478 (22.99) |
71/355 (20.00) |
72 (60, 81) |
| TB/MDR-TB history |
No |
145 (7.15) |
16/105 (15.24) |
85 (76, 91) |
0.12 |
| |
Yes |
1,8882 (92.85) |
348/1,479 (23.53) |
70 (65, 74) |
| HIV status |
Negative |
859 (41.32) |
101/656 (15.40) |
76 (60, 82) |
<0.05 |
| |
Positive |
554 (26.65) |
169/445 (37.98) |
54 (47, 61) |
| |
Status unknown |
666 (32.03) |
97/518 (26) |
79 (74, 83) |
| Ethambutol Resistance |
Known |
1,444 (55.03) |
146/911 (16.03) |
78 (72, 82) |
<0.05 |
| |
Unknown |
935 (44.97) |
221/708 (31.21) |
62 (56, 68) |
| Kanamycin Resistance |
Known |
437 (20.97) |
62/382 (16.23) |
76 (68, 82) |
<0.05 |
| |
Unknown |
1,643 (79.03) |
305/1,237 (24.66) |
69 (64, 73) |
| Ofloxacin/Ciprofloxacin Resistance |
Known |
326 (15.68) |
57/286 (19.93) |
71 (62, 79) |
0.19 |
| |
Unknown |
1,753 (84.32) |
310/1,333 (23.26) |
71 (66, 75) |
aFrequencies and percentages based on complete observed data, so the totals do not necessary equal those in the third column, which a gives a count of the subjects enrolled. |
